{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:30:37Z","timestamp":1761863437690},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although bivalirudin has been shown to reduce bleeding events in patients undergoing percutaneous coronary intervention, residual concerns remain about a possible higher risk of early (within 30 days) stent thrombosis (ST). Therefore, we performed a meta-analysis of randomised trials reporting ST events with bivalirudin compared to other antithrombotic therapies (heparins \u00b1 glycoprotein IIb\/IIIa inhibitors). A systematic literature search of electronic resources was performed through May, 2014. The primary endpoint was definite early ST, according to Academic Research Consortium criteria. Secondary endpoints included: all-cause death, myocardial infarction and major bleeding. A total of 11 trials, including 16,415 patients, were accrued. Compared to other regimens, bivalirudin significantly increased the risk of early ST (odds ratio [OR]=1.80; 95 % confidence interval [CI], 1.28 2.52; p=0.0007) and reduced the risk of major bleeding (OR [95 %CI]=0.64 [0.51 0.82], p=0.0003), with a comparable risk of mortality or myocardial infarction. The higher risk of early ST was mainly attributable to acute (OR [95 % CI] =4.33 [2.33 8.05], p &lt; 0.001) than subacute (OR [95 % CI] =0.89 [0.53 1.50], p =0.67) ST events (p for interaction &lt; 0.001). Non-fatal myocardial infarction was the most common presentation (83 %) of early ST events, while death occurred infrequently (about 5 %). In conclusion, in patients undergoing PCI, bivalirudin compared to heparins is associated with a higher risk of early ST, which is mainly related to more frequent acute events. Further studies are required to evaluate alternative strategies to mitigate this risk, without hampering the benefits derived from the reduction in bleeding events with bivalirudin.<\/jats:p>","DOI":"10.1160\/th14-08-0646","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T05:38:38Z","timestamp":1423719518000},"page":"1010-1020","source":"Crossref","is-referenced-by-count":17,"title":["Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary intervention"],"prefix":"10.1160","volume":"113","author":[{"given":"Raffaele","family":"Piccolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara De","family":"Biase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"D\u2019Anna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Trimarco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Piscione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Galasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2017,11,24]]},"reference":[{"key":"10.1160\/TH14-08-0646-1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685974"},{"key":"10.1160\/TH14-08-0646-2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.109.884478"},{"key":"10.1160\/TH14-08-0646-3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1160\/TH07-11-0693","volume":"99","author":"Warkentin","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH14-08-0646-4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.112.264903"},{"key":"10.1160\/TH14-08-0646-5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1160\/TH09-05-0287","volume":"102","author":"De","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH14-08-0646-6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.842757"},{"key":"10.1160\/TH14-08-0646-7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.07.016"},{"key":"10.1160\/TH14-08-0646-8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1312702"},{"key":"10.1160\/TH14-08-0646-9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"10.1160\/TH14-08-0646-10","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2380"},{"key":"10.1160\/TH14-08-0646-11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.6.676"},{"key":"10.1160\/TH14-08-0646-12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096127"},{"key":"10.1160\/TH14-08-0646-13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.013"},{"key":"10.1160\/TH14-08-0646-14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"10.1160\/TH14-08-0646-15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.04.017"},{"key":"10.1160\/TH14-08-0646-16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.12.001"},{"key":"10.1160\/TH14-08-0646-17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu182"},{"key":"10.1160\/TH14-08-0646-18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311096"},{"key":"10.1160\/TH14-08-0646-19","doi-asserted-by":"crossref","unstructured":"Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014, Epub ahead of print","DOI":"10.1016\/S0140-6736(14)60924-7"},{"key":"10.1160\/TH14-08-0646-20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708191"},{"key":"10.1160\/TH14-08-0646-21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802944"},{"key":"10.1160\/TH14-08-0646-22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109596"},{"key":"10.1160\/TH14-08-0646-23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.06.035"},{"key":"10.1160\/TH14-08-0646-24","unstructured":"Briguori C. Novel Approaches in Preventing or Limiting Event (NAPLES) III Trial. Presented at the American College of Cardiology Scientific Session, Washington, DC, March 29, 2014. Available at: http: \/\/www.cardiosource.org\/~\/media\/Files\/Science and Quality\/Clinical Trials\/ACC 14 Slides\/NAPLES III ACC14 Presentation Slides.ashx"},{"key":"10.1160\/TH14-08-0646-25","doi-asserted-by":"publisher","DOI":"10.1111\/joic.12005"},{"key":"10.1160\/TH14-08-0646-26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.073"},{"key":"10.1160\/TH14-08-0646-27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.612812"},{"key":"10.1160\/TH14-08-0646-28","first-page":"132","volume":"173","author":"Chatterjee","year":"2013","journal-title":"J Am Med Assoc Intern Med"},{"key":"10.1160\/TH14-08-0646-29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.03.003"},{"key":"10.1160\/TH14-08-0646-30","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV9I1A17"},{"key":"10.1160\/TH14-08-0646-31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.055"},{"key":"10.1160\/TH14-08-0646-32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.12.042"},{"key":"10.1160\/TH14-08-0646-33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.01.038"},{"key":"10.1160\/TH14-08-0646-34","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2011.224709"},{"key":"10.1160\/TH14-08-0646-35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61216-2"},{"key":"10.1160\/TH14-08-0646-36","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(14)60027-9"},{"key":"10.1160\/TH14-08-0646-37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323"},{"key":"10.1160\/TH14-08-0646-38","doi-asserted-by":"publisher","DOI":"10.1177\/0003319712467530"},{"key":"10.1160\/TH14-08-0646-39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.11.028"},{"key":"10.1160\/TH14-08-0646-40","doi-asserted-by":"crossref","unstructured":"Tarantini G, Brener SJ, Barioli A, et al. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials. Am Heart J 2014; 167: 401-412 e406","DOI":"10.1016\/j.ahj.2013.11.013"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH14-08-0646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T17:48:46Z","timestamp":1566323326000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH14-08-0646"}},"subtitle":["A meta-analysis of randomised clinical trials"],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":40,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2017,11,24]]},"published-print":{"date-parts":[[2015,9]]}},"URL":"https:\/\/doi.org\/10.1160\/th14-08-0646","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}